TY - JOUR T1 - 277 Detection of androgen receptor incidence in gynaecological cancers and its relevance in high grade serous epithelial ovarian cancers JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A117 LP - A117 DO - 10.1136/ijgc-2019-IGCS.277 VL - 29 IS - Suppl 3 AU - MI Anjum Y1 - 2019/09/01 UR - http://ijgc.bmj.com/content/29/Suppl_3/A117.1.abstract N2 - Objectives The aim of this study is to estimate the incidence of expression of androgen receptor (AR) in gynaecological cancers and association of expression of AR status with stage, cytoreduction and progression free survival in high grade epithelial ovarian cancers.Methods This is a prospective observational study of 20 months duration,conducted in department of gynaecological oncology at AIMS, Kochi. The study group comprised of 99 consecutive gynaecologicals cancers between 2016 and 2018 in whom immunohistochemical staining for AR was done in tissue samples.Results were analysed using IBM SPSS version 20.0, Pearson Chi square test was used.Results In the course of our study, ARs were differently expressed in different histotypes of gynaecological cancers cancer (n=99) AR expression is 45%(n=9/20) of 20 carcinoma endometrium,9.1%(n=1/11)cases in cervical cancers and 100% in sarcoma and ovarian cancers 40.6% (n=64),more highly expressed in HGSC 61.5%(n=41/64) but its association with AR is not statistically significant (p=0.78).Of note, all of the HGSC samples AR expression was associated with neither stage,cytoreduction of EOC nor progression free/overall survival. AR-positivity was associated with improved OS, and AR negativity was associated with recurrence but not reaching a statistical significance.Conclusions An effective and clinically applicable molecular classification of HGSC can be grouped in our cohort based on ER,PR and AR receptor status and observed that PR positive subgroup were younger compared to the other groups and recurrences were more with the PR absent subgroup and both being statistically significant.Study describes patterns of AR expression in a spectrum of cancers, and potential to exploit this knowledge in clinical therapeutic setting. ER -